Skip to main content

Advertisement

Log in

Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1

Surgery Today Aims and scope Submit manuscript

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominantly inherited endocrine tumor syndrome characterized by tumor development in various endocrine organs such as the parathyroid, endocrine pancreas, anterior pituitary and adrenal cortex. The first extensive database for Asian patients with MEN1 was established by the MEN Consortium of Japan. Although the clinical features of Japanese patients with MEN1 are similar to those from Western countries, there are several characteristic differences between them. In particular, gastroenteropancreatic neuroendocrine tumor (GEPNET) is seen in approximately 60 % of patients with MEN1 in Japan. Although its development is the strongest prognostic factor in patients with MEN1, the characteristics of MEN1-associated GEPNET still remain unclear. This is especially true for the differences in clinical features of GEPNET with and without MEN1. Improved long-term survival is obtained by curative surgery for patients with MEN1-associated GEPNET. The current surgical indications are expanding even in patients with hepatic metastases because of the improved surgical outcome. This article reviews the clinical characteristics in these patients with a particular focus on surgery, diagnosis, surgical indications, surgical method, and surgical outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954;16:363–71.

    Article  PubMed  CAS  Google Scholar 

  2. Wermer P. Endocrine adenomatosis, peptic ulcer disease in a large kindred: inherited multiple tumors, mosaic pleiotropism in man. Am J Med. 1963;35:205–8.

    Article  PubMed  CAS  Google Scholar 

  3. Sakurai A, Suzuki S, Kosugi S, Okamoto T, Uchino S, Miya A, et al. Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of multicenter database. Clin Endocrinol. 2012;76(4):533–9.

    Article  Google Scholar 

  4. Gibril F, Venzon DJ, Ojeburu JV, Bashir S, Jensen RT. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab. 2001;86(11):5282–93.

    Article  PubMed  CAS  Google Scholar 

  5. Glascock JM, Carty SE. Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg Oncol. 2002;11:143–50.

    Article  PubMed  Google Scholar 

  6. Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg Today. 2011;41(10):1332–43.

    Article  PubMed  Google Scholar 

  7. Dickson PV, Rich TA, Xing Y, Cote GJ, Wang H, Perrier ND, et al. Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery. 2011;150:1143–52.

    Article  PubMed  Google Scholar 

  8. Brandi ML, Gagel RF, Angeli A, Bilezkian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.

    Article  PubMed  CAS  Google Scholar 

  9. Fraker DL, Norton JA, Alexander HR, Venzon DJ, Jensen RT. Surgery in Zollinger–Ellison syndrome alters the natural history of gastrinoma. Ann Surg. 1994;220:320–30.

    Article  PubMed  CAS  Google Scholar 

  10. Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244:410–9.

    PubMed  Google Scholar 

  11. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg. 2005;242:757–66.

    Article  PubMed  Google Scholar 

  12. Lévy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D, et al. Prevalence, characteristics and prognosis of MEN1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28(11):1075–81.

    Article  PubMed  Google Scholar 

  13. Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Quart J Med. 1996;89(9):653–69.

    Article  CAS  Google Scholar 

  14. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234–43.

    Article  PubMed  Google Scholar 

  15. Waldmann J, Bartsch DK, Kann PH, Fendrich V, Rothmund M, Langer P. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbeck’s Arch Surg. 2007;392:437–43.

    Article  CAS  Google Scholar 

  16. Kann PH, Bittinger F, Engelbach M, Bohner S, Weis A, Beyer J. Endosonography of insulin-secreting and clinically non-functioning neuroendocrine tumors of the pancreas: criteria for benignancy and malignancy. Euro J Med Res. 2001;6:385–90.

    CAS  Google Scholar 

  17. Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose KJ, Behr T, Langer P. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer. 2006;13:1195–202.

    Article  PubMed  CAS  Google Scholar 

  18. Schaefer S, Shipotko M, Meyer S, Ivan D, Klose KJ, Waldmann J, Langer P, Kann PH. Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Euro J Endocrinol. 2008;158:699–704.

    Article  CAS  Google Scholar 

  19. Imamura M, Takahashi K, Adachi H, Minematsu S, Shimada Y, Naito M, Suzuki T, Tobe T, Azuma T. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger–Ellison syndrome. Ann Surg. 1987;205:230–9.

    Article  PubMed  CAS  Google Scholar 

  20. Imamura M, Takahashi K, Isobe Y, Hattori Y, Satomura K, Tobe T. Curative resection of multiple gastrinoma aided by selective arterial injection test and intraoperative secretin test. Ann Surg. 1989;210:710–8.

    Article  PubMed  CAS  Google Scholar 

  21. Imamura M, Komoto I, Ota S, Hiratsuka T, Kosugi S, Doi R, Awane M, Inoue N. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patient. World J Gastroenterol. 2011;17:1343–53.

    Article  PubMed  Google Scholar 

  22. Imamura M, Komoto I. Gastrinoma. In: Hubbard J, Inabnet WB, Lo CY, editors. Endocrine surgery: principles and practice (Springer specialist surgery series). London: Springer; 2009. p. 507–21.

    Google Scholar 

  23. Makuuchi M, Hasegawa H, Yamazaki S. Intraoperative ultrasonic examination for hepatectomy. Ultrasound Med Biol. 1983;Suppl 2:493–7.

    PubMed  CAS  Google Scholar 

  24. Zhang K, Kokudo N, Hasegawa K, Arita J, Tang W, Aoki T, et al. Detection of new tumors by intraoperative ultrasonography during repeated hepatic resections for hepatocellular carcinoma. Arch Surg. 2007;142(12):1170–5.

    Article  PubMed  Google Scholar 

  25. Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006;30:643–53.

    Article  PubMed  Google Scholar 

  26. Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw. 2006;4(2):148–53.

    PubMed  Google Scholar 

  27. Plökinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors: a consensus statement of behalf of the European Neuroendocrine Tumor Society (ENETS). Neuroendocrinology. 2004;80(6):394–424.

    Article  Google Scholar 

  28. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease: results in the treatment of 40 patients with Zollinger–Ellison syndrome, hypoglycemia or both. J Intern Med. 1998;243:495–500.

    Article  PubMed  CAS  Google Scholar 

  29. Imamura M. Changing clinical practice for NET. Igaku no Ayumi. 2008;224(10):753–6. (in Japanese).

    Google Scholar 

  30. Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87:47–62.

    Article  PubMed  Google Scholar 

  31. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776–83.

    Article  PubMed  Google Scholar 

  32. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.

    Article  PubMed  Google Scholar 

  33. Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmnesh R, Sauvanet A, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer. 2009;16:977–90.

    Article  PubMed  CAS  Google Scholar 

  34. Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17:3129–36.

    Article  PubMed  Google Scholar 

  35. Ellison EC, Sparks J, Verducci JS, Johnson JA, Muscarella P, Bloomston M, et al. 50-year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg. 2006;202(6):897–905.

    Article  PubMed  Google Scholar 

  36. Imamura M, Komoto I, Doi R, Onodera H, Kobayashi H, Kawai Y. New pancreas-preserving total duodenectomy technique. World J Surg. 2005;29:203–7.

    Article  PubMed  Google Scholar 

  37. Lopez CL, Waldmann J, Fendrich V, Langer P, Kann PH, Bratsch DK. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg. 2011 [Epub ahead of print].

  38. Maeda H, Hanazaki K. Pancreatogenic diabetes after pancreatic resection. Pancreatology. 2011;11:268–76.

    Article  PubMed  Google Scholar 

  39. Jethwa P, Sodergren M, Lala A, Webber J, Buckels JA, Bramhall SR, Mirza DF. Diabetic control after total pancreatectomy. Dig Liver Dis. 2006;38:415–9.

    Article  PubMed  CAS  Google Scholar 

  40. Kono T, Hanazaki K, Yazawa K, Ashizawa S, Fisher WE, Wang XP, et al. Pancreatic polypeptide administration reduces insulin requirements of artificial pancreas in pancreatectomized dogs. Artif Organs. 2005;29:83–7.

    Article  PubMed  Google Scholar 

  41. Okabayashi T, Nishimori I, Maeda H, Yamashita K, Yatabe T, Kohsaki T, et al. Continuous postoperative blood glucose monitoring and control by artificial pancreas in patients having pancreatic resection: a prospective randomized clinical trial. Arch Surg. 2009;144:933–7.

    Article  PubMed  Google Scholar 

  42. Hanazaki K, Okabayashi T, Maeda H. Tight glycemic control using an artificial pancreas to control perioperative hyperglycemia decreases surgical site infection in pancreatectomized or hepatectomized patients. Ann Surg. 2009;250:351–2.

    Article  Google Scholar 

  43. Hanazaki K, Maeda H, Okabayashi T. Relationship between perioperative glycemic control and postoperative infections. World J Gastroenterol. 2009;15:4122–5.

    Article  PubMed  Google Scholar 

  44. Hanazaki K, Maeda H, Okabayashi T. Tight perioperative glycemic control using an artificial endocrine pancreas. Surg Today. 2010;40(1):1–7.

    Article  PubMed  Google Scholar 

  45. Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Lévy P, Vilgrain V, et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg. 2008;247:659–65.

    Article  PubMed  Google Scholar 

  46. Bechstein WO, Neuhaus P. Liver transplantation for hepatic metastases of neuroendocrine tumors. Ann N Y Acad Sci. 1994;733:507–14.

    Article  PubMed  CAS  Google Scholar 

  47. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998;66:1307–12.

    Article  PubMed  CAS  Google Scholar 

  48. Ahlman H, Friman S, Cahlin C, Nilsson O, Jansson S, Wängberg B, et al. Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:265–9.

    Article  PubMed  Google Scholar 

  49. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 2006;12:448–56.

    Article  PubMed  Google Scholar 

  50. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007;13:327–33.

    Article  PubMed  Google Scholar 

  51. Mathe Z, Tagkalos E, Paul A, Molmenti EP, Kobori L, Fouzas I, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival based analysis. Transplantation. 2011;91(5):575–82.

    Article  PubMed  Google Scholar 

  52. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANTES treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735–52.

    Article  PubMed  Google Scholar 

  53. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–92.

    Article  PubMed  CAS  Google Scholar 

  54. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572–81.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank other members of the MEN Consortium of Japan for their helpful work. The activity of the MEN Consortium of Japan has been supported by a Grant from the Ministry of Health, Welfare and Labor, Government of Japan. [H22-Nanchi-Ippan-105] (to A. Sakurai) This activity has also been selected as one of the “high-profile clinical issues” of the Japan Endocrine Society.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kazuhiro Hanazaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanazaki, K., Sakurai, A., Munekage, M. et al. Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. Surg Today 43, 229–236 (2013). https://doi.org/10.1007/s00595-012-0376-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-012-0376-5

Keywords

Navigation